News

Video

Factors in Frontline Treatment Decision Making for Endometrial Cancer

Author(s):

Ritu Salani, MD,Bhavana Pothuri, MD

Key factors influencing frontline treatment choices in endometrial cancer, including biomarker status, comorbidities, guidelines, and patient preferences, with a focus on the evolving landscape of therapies.

Related Videos
3 experts are featured in this series.
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
1 expert in this video
Related Content
Lunresertib Plus Camonsertib in Endometrial, Ovarian Cancer | Image Credit: © Katsyarina - stock.adobe.com
December 19th 2024

Lunresertib Plus Camonsertib Produces Durable Responses in Advanced Endometrial, Ovarian Cancer

Bradley J. Monk, MD, FACOG, FACS; Paolo Tarantino, MD
January 11th 2024

Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

Stephanie Gaillard, MD, PhD, of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
December 10th 2024

New ADCs Join NCCN Guidelines for Gynecologic Cancers Representing Step Forward

Diane M. Simeone, MD; Marwan G. Fakih, MD
December 18th 2023

Simeone and Fakih Detail Research Objectives With A2B530 in CEA-Expressing Solid Tumors

FDA
December 5th 2024

FDA Grants Fast Track Designation to CRB-701 in Relapsed/Refractory Cervical Cancer

Cadonilimab Plus Chemotherapy in Cervical Cancer | Image Credit: © Dr_Microbe - stock.adobe.com
December 3rd 2024

Cadonilimab Plus Chemotherapy Provides Frontline Survival Benefit in Metastatic Cervical Cancer